Table 2. Baseline laboratory investigations in HIV TBM patients.
| Variable | Normal range | All patients (n = 58) | Deaths (n = 39) | Survivors (n = 11) |
| CD4 count, cells/mm3 | 500–1500 | 32 (2–285)3 | 31 (2–285) | 37 (16–141) |
| Haematocrit % | 37–47 | 34.8 (19.6–45.1) | 34.9 (19.6–45.1) | 35.4 (28.8–42.2) |
| Blood white cell count×109/l | 5–10 | 8.9 (2.7–21.9) | 8.9 (2.7–20.6) | 8.7 (3.7–21.9) |
| Blood neutrophil % | 55–75 | 80.1 (41.6–92.9) | 80.6 (41.6–92.9) | 80.3 (61.2–91.2) |
| Blood lymphocyte % | 20–40 | 10.0 (3–47.7) | 9.9 (3–47.7) | 8.8 (4.3–18.2) |
| Blood platelet count×109/l | 200–400 | 244 (75–604) | 263 975–604) | 235 (94–448) |
| Serum sodium mmol/l | 35–145 | 127.8 (110–148) | 125.7 (110–148) | 135 (115–140) |
| Serum potassium mmol/l | 3.5–5.0 | 3.9 (2.9–5.8) | 3.9 (2.9–5.8) | 3.9 (3.2–4.7) |
| Serum creatinine µmol/l | 53–120 | 75.5 (9.4–276) | 71 (9.4–276) | 80 (53–164) |
| Serum bilirubin µmol/l | ≤17 | 8 (1–47)1 | 8.3 (1–47) | 8 (5–17) |
| Serum aspartate transaminase IU/l | ≤37 | 41 (18–599)2 | 46 (18–599) | 40 (22–158) |
| Serum alanine transaminase IU/l | ≤40 | 42 (17–621)2 | 41.5 (17–621) | 60 (22–240) |
Notes: Data are expressed as median (range), unless otherwise noted. Comparison of variables between deaths and survivors excludes patients who withdrew or were lost to follow-up.
1
data from 52 patients.
2
data from 55 patients.
3
data from 50 patients.